Trial Profile
A Pilot Open Label Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy Including Lenalidomide on Cancer Related Sleep Disturbances in Chronic Lymphocytic Leukemia (CLL) and Breast Cancer Patients Experiencing Clinically Significant Fatigue
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 06 Jul 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary)
- Indications Breast cancer; Chronic lymphocytic leukaemia
- Focus Pharmacodynamics
- 03 Aug 2020 Status changed from active, no longer recruiting to completed.
- 30 Jun 2020 Planned End Date changed from 1 Nov 2020 to 30 Nov 2021.
- 30 Jun 2020 Planned primary completion date changed from 1 Nov 2019 to 30 Nov 2020.